Výsledky vyhledávání

Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice

Autor: Sunil M. Kurian, Didier A. Mandelbrot, D. Maluf, C. Schieve, D. Lee, John J. Friedewald, A. Patel, James C. Rice, S. Rose, Richard J. Knight, Michael Abecassis, M. R. First, V. R. Peddi, Roslyn B. Mannon, Christopher L. Marsh, P. Lewis, J. David

Publikováno v: Transplantation Proceedings. 51:729-733

Background TruGraf v1 is a well-validated DNA microarray-based test that analyzes blood gene expression profiles as an indicator of immune status in kidney transplant recipients with stable renal function. Methods In this study, investigators assesse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac36e8627c7dac4fdb9dd696848e9f06
https://doi.org/10.1016/j.transproceed.2018.10.024

Zobrazit plný text záznamu

Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function

Autor: Sunil M. Kurian, J. David, Jamie Case, Bethany Barrick, Roslyn B. Mannon, Christopher L. Marsh, Michael Abecassis, S. Rose, James C. Rice, Didier A. Mandelbrot, Thomas Whisenant, D. Maluf, A. Patel, John J. Friedewald, D. Lee, C. Schieve, Richard J. Knight, M. R. First, V. R. Peddi

Publikováno v: Transplantation Proceedings. 51:722-728

TruGraf v1 is a laboratory-developed DNA microarray-based gene expression blood test to enable proactive noninvasive serial assessment of kidney transplant recipients with stable renal function. It has been previously validated in patients identified

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96aef12ca09a07f8fbd0d1e1495a39b7
https://doi.org/10.1016/j.transproceed.2019.01.054

Zobrazit plný text záznamu

Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus

Autor: Kevin McCague, Dhavalkumar D. Patel, Shamkant Mulgaonkar, Fuad S. Shihab, David Shaffer, V R Peddi, Y. Qazi

Publikováno v: American Journal of Transplantation

A key objective in the use of immunosuppression after kidney transplantation is to attain the optimal balance between efficacy and safety. In a phase 3b, multicenter, randomized, open‐label, noninferiority study, the incidences of clinical events,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfb35d8dd654c2e488b5ee511accab00
https://doi.org/10.1111/ajt.14215

Zobrazit plný text záznamu

Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data

Autor: Bruce Kaplan, Fuad S. Shihab, Shamkant Mulgaonkar, Kevin McCague, V R Peddi, Dhavalkumar D. Patel, Serdar Yilmaz, F. Luan, Stephen J. Tomlanovich, David Shaffer, Dean Y Kim, Y. Qazi

Publikováno v: American Journal of Transplantation. 17:1358-1369

In this 12-month, multicenter, randomized, open-label, noninferiority study, de novo renal transplant recipients (RTxRs) were randomized (1:1) to receive everolimus plus low-dose tacrolimus (EVR+LTac) or mycophenolate mofetil plus standard-dose Tac (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa8ba8ab0ff1127ec1e8074998a2c2e5
https://doi.org/10.1111/ajt.14090

Zobrazit plný text záznamu

Recurrent and de novo renal diseases after renal transplantation: A report from the renal allograft disease registry

Autor: S, Hariharan, V R, Peddi, V J, Savin, C P, Johnson, M R, First, A M, Roza, M B, Adams

Publikováno v: American Journal of Kidney Diseases. 31:928-931

Recurrent or de novo glomerular disease is an important cause of graft dysfunction and eventual loss. Cyclosporine A (CyA) has improved short-term renal allograft outcome but has not altered long-term graft survival. The purpose of the current study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2621cf3eb3af08a675eb165a9bc04760
https://doi.org/10.1053/ajkd.1998.v31.pm9631835

Zobrazit plný text záznamu

Catastrophic secondary antiphospholipid syndrome with concomitant antithrombin III deficiency

Autor: V R Peddi, Kant Ks

Publikováno v: Journal of the American Society of Nephrology. 5:1882-1887

The association between thrombotic events and primary or secondary antiphospholipid/anticardiolipin syndrome is now well recognized. A spectrum of renal involvement ranging from glomerular thrombosis to renal infarction has been described. A case of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::854d4d62e2549c2f6f51023b34fafa32
https://doi.org/10.1681/asn.v5111882

Zobrazit plný text záznamu

Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients

Autor: Robert A. Fisher, T. Shah, Shamkant Mulgaonkar, Goran B. Klintmalm, Sundaram Hariharan, Steven Steinberg, N. Lawendy, Jonathan S. Bromberg, C. Wang, Flavio Vincenti, Daniel C. Brennan, G. Chan, Stephan Busque, V R Peddi, Douglas P. Slakey, Joseph R. Leventhal

Publikováno v: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 9(8)

This randomized, pilot study compared the Janus kinase inhibitor CP-690,550 (15 mg BID [CP15] and 30 mg BID [CP30], n = 20 each) with tacrolimus (n = 21) in de novo kidney allograft recipients. Patients received an IL-2 receptor antagonist, concomita

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41d2c020039814fbdd4cf03d15553a3c
https://pubmed.ncbi.nlm.nih.gov/19660021

Zobrazit plný text záznamu

Recent advances in immunosuppressive therapy for renal transplantation

Autor: V R, Peddi, M R, First

Publikováno v: Seminars in dialysis. 14(3)

Recent advances in immunosuppression have focused on more effective, safer, and targeted therapies that have resulted in improved short- and intermediate-term renal allograft survival. During the past decade there has been a marked decrease in acute

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8a1157015af039ff981d204d649c7690
https://pubmed.ncbi.nlm.nih.gov/11422929

Zobrazit plný text záznamu

Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR)

Autor: S, Hariharan, M B, Adams, D C, Brennan, C L, Davis, M R, First, C P, Johnson, R, Ouseph, V R, Peddi, C J, Pelz, A M, Roza, F, Vincenti, V, George

Publikováno v: Transplantation. 68(5)

Short-term and long-term results of renal transplantation have improved over the past 15 years. However, there has been no change in the prevalence of recurrent and de novo diseases. A retrospective study was initiated through the Renal Allograft Dis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8e9624517519d3b266b5fb39ba4cdb55
https://pubmed.ncbi.nlm.nih.gov/10507481

Zobrazit plný text záznamu

A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management

Autor: D E, Dean, S, Kamath, V R, Peddi, T J, Schroeder, M R, First, T, Cavallo

Publikováno v: Transplantation. 68(5)

We sought to determine whether diagnoses established through the Banff schema for evaluation of renal allograft pathology have implications for clinical management, compared with diagnoses established using descriptive terminology.All patients includ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::52fb91851facb4bcee47c20077f633c1
https://pubmed.ncbi.nlm.nih.gov/10507482

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání